INTRODUCTION AND OBJECTIVES:
The use of concomitant hormonal therapy (HT) in patients treated with salvage radiation therapy (SRT) after radical prostatectomy (RP) has shown to be beneficial on strong clinical endpoints. However, it is unknown whether the addition of HT in the setting of late SRT (at PSA >0.5 ng/ml) can lead to similar outcomes of early SRT (at PSA <0.5 ng/ml). We hypothesized that use of HT in the late salvage setting is not able to compensate for a nontimely use of SRT, even using higher doses and wider fields of radiation METHODS: The study included 947 node negative patients who received SRT at seven referral centres for recurrent prostate cancer after RP. The administered dose, the RT field, and the use of concomitant HT were left at the discretion of the treating physician. The outcome consisted of clinical recurrence (CR) after SRT identified by imaging. Patients were divided into three groups: (1) PSA level at SRT 0.5 ng/ml without concomitant HT; (2) PSA level at SRT >0.5 ng/ ml without concomitant HT; (3) PSA level at SRT >0.5 ng/ml with concomitant HT. Kaplan-Meier plots assessed the CR-free survival among groups. Finally, multivariable Cox regression analysis tested the association of each group with CR. Covariates consisted of pT stage, pathological Gleason score, SRT dose, and SRT field (prostatic fossa vs. whole pelvis) RESULTS: Overall, 503 (53%) patients were treated in the early salvage setting (Group 1), whereas 243 (26%) and 210 (22%) patients were treated at PSA level >0.5 ng/ml without (Group 2) and with (Group 3) concomitant HT. Whole pelvis SRT was delivered to 156 (24%) patients, whereas median SRT dose was 66 Gy. At a median follow-up of 74 months, 114 (12%) patients developed CR. CR-free survival at 8 years was 74%, 64%, and 70% in the three groups, respectively (all p<0.0001). These results were confirmed at multivariable analysis, where men in Group 2 (HR: 1.75; p[0.001) and Group 3 (HR: 1.45; p[0.012) had significantly higher risk of CR. Interestingly, SRT dose (HR: 0.89, p[0.2) and SRT field (HR: 0.68, p[0.2) were not significantly associated with CR in any of the tested groups CONCLUSIONS: Early delivery of SRT represents the most relevant factor for cancer control in men treated for PSA relapse after surgery. Use of concomitant HT in patients treated at PSA levels >0.5 ng/ml partially improves cancer control when compared to a late SRT strategy without HT, but it does not fully compensate for a nontimely use of SRT. Men with early SRT without HT showed indeed the lowest rate of recurrence over time, regardless of dose and fields of radiation
